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The ability to biochemically or genetically manipulate the composition of a cell surface has provided new avenues for fundamental studies of cell-surface recognition. Methods for "cell surface engineering" have also enabled the chemical restructuring of cell surfaces for tailored purposes (1) . One approach involves the metabolic delivery of unnatural moieties to cell surface glycoconjugates via pathways for oligosaccharide biosynthesis (2) . An unnatural monosaccharide precursor is "fed" to cells and processed by the biosynthetic machinery into a novel product that is presented on the cell surface. The process requires that biosynthetic enzymes transform the modified substrate with relative efficiency compared to endogenous natural substrates.
The pathway for sialic acid biosynthesis shows tolerance for unnatural substrates and consequently has attracted attention as a vehicle for metabolic cell surface engineering. Shown in Figure 1 , sialic acid biosynthesis comprises a chemically and topologically complex set of events.
N-Acetylmannosamine (ManNAc), the first committed precursor, is either biosynthesized from UDP-N-acetylglucosamine (UDP-GlcNAc), obtained from the extracellular environment (3), or derived from GlcNAc via the action of GlcNAc 2-epimerase (4). ManNAc undergoes a series of enzymatic transformations resulting in the formation of CMP-sialic acid in the nucleus. This activated sugar is then transported to the Golgi compartment where it acts as the donor for glycosylation of an elongating glycan by one of a family of sialyltransferases. The sialylated glycoprotein or glycolipid is then secreted or delivered to the plasma membrane by the secretory machinery.
In vitro biochemical assays have determined that several enzymes in this pathway can utilize unnatural substrates with elongated N-acyl groups, as well as modifications at other positions (5) (6) (7) (8) (9) (10) (11) (12) . Reutter and coworkers exploited the permissivity of these enzymes and transport proteins to express unnatural sialic acids on the surface of living cells (13) . Cells that were incubated with N-propanoyl, N-butanoyl or N-pentanoylmannosamines generated the corresponding unnatural sialosides on cell-surface glycoconjugates and secreted glycoproteins.
This phenomenon was used to alter the proliferation of specific cell types in a mixed population 5 (14) and the susceptibility of cells to viral infection (15, 16) . More recently, Schnaar and coworkers demonstrated that metabolic conversion of N-glycolylmannosamine to the corresponding N-glycolyl sialic acid abrogated the binding of myelin-associated glycoprotein (MAG) to neuroblastoma-glioma hybrid cells (17) .
Our laboratory has extended this substrate-based approach to introduce chemically reactive functional groups into cell surface sialosides. For example, inclusion of a ketone group in the elongated N-acyl substituent of a ManNAc analog allows further elaboration of the corresponding cell surface sialic acid by selective chemical reaction with a hydrazide or aminooxy conjugate (18) . Applications of ketone-based cell surface remodeling include selective delivery of diagnostic or therapeutic agents to cells based on their relative levels of sialic acid (19) , glycoform remodeling (20) , and construction of novel viral receptors (21) . These studies all utilized a single mannosamine analog, N-levulinoylmannosamine (ManLev, Figure 2A , compound 3a). To further expand sialic-acid based cell surface engineering, new chemical coupling partners such as azide-phosphine pairs are being explored (22) . Still, the extent of unnatural substrate tolerance and the possible preference for some analogs over others have not been examined in detail. Such information is crucial for expanding the applications of sialic acidbased cell surface engineering, and for understanding the cellular mechanisms for substrate selection.
In this study, we addressed the scope and limitations of unnatural substrate tolerance in the sialic acid biosynthetic pathway. A panel of unnatural mannosamine analogs (shown in Figure   2A ) was synthesized, each bearing a ketone group on a side-chain that replaces the N-acetamido group. In each case, the ketone provided a chemical cell-surface marker for quantifying unnatural sialoside expression. By systematically varying the length or size of the modified N-acyl group, we explored the global substrate requirements of the complete pathway in intact cells. In order to dissect the detailed metabolism of these compounds within a cell, radiolabel HPLC, colorimetric and mass spectrometry assays were developed to measure intracellular levels of the metabolites 6 downstream of ManNAc, namely ManNAc-6-phosphate, sialic acid and CMP-sialic acid, as well as their unnatural analogs. The relative amounts of these metabolic products in cells treated with natural and unnatural substrates were compared in order to identify the bottleneck step for metabolism of unnatural mannosamines. These experiments indicated that the phosphorylation step of the pathway was either inefficient or bypassed; thus, the ManNAc 6-kinase was tested in vitro to verify the hypothesis that this enzyme acts as a bottleneck for unnatural sialic acid biosynthesis.
Materials and Methods

Materials
Biotin hydrazide, Dulbecco's PBS, FITC-labeled avidin, sodium azide, trypsin-ETDA, ATP, PEP, NADH, pyruvate kinase, lactate dehydrogenase and penicillin-streptomycin were purchased from Sigma. DTT was from New England Biolabs, RPMI medium 1640 was from Life Technologies, Inc., DME medium was from CellGro and fetal bovine serum (FBS) was from HyClone Laboratory. Hygromycin B (HygB) and geneticin were from Boehringer. All protease inhibitors were from Sigma except Pefabloc®, which was from Boehringer-Mannheim. [1- 14 C]-mannosamine hydrochloride was purchased from American Radiolabeled Chemicals. All reagents used for chemical synthesis were obtained from commercial suppliers and were used without further purification. Fast atom bombardment (FAB+) mass spectra were obtained at the U. C.
Berkeley Mass Spectral Laboratory. Mass spectra of acetylated mannosamines were obtained with a Bruker 3000 electrospray ionization-ion trap instrument in the positive mode by flowinjection in acetonitrile. Mass spectra of sialic acids were obtained by electrospray ionization in the negative mode using ESI-MS (Hewlett Packard 1100 Series MSD). Cell densities were determined using a Coulter Counter-ZM. Flow cytometry analysis was performed on a Coulter EPICS  XL-MCL cytometer using a 488 nm argon laser. At least 10 4 viable cells were analyzed from each sample. High pH anion exchange chromatography (HPAEC) was performed using a 7 Dionex system equipped with a CarboPac TM PA1 column, a pulsed amperometric detector (PAD) and an in-line flow scintillation counter (Packard, Meriden, CT). The system was run at a flow rate of 1 ml/min. All biological experiments were performed in duplicate.
Cell culture conditions
Jurkat cells were grown in RPMI medium 1640 supplemented with 5% FBS and penicillin/streptomycin. HeLa cells were grown in DMEM supplemented with 10% FBS and penicillin/streptomycin. HL-60 cells were grown in RPMI medium 1640 supplemented with 10%
FBS and penicillin/streptomycin.
General procedure for the synthesis of ketone-containing mannosamine derivatives
To a solution of the keto-acid (1.1 eq) in distilled THF (~0.2 M) was added triethylamine (1.1 eq) under nitrogen, and the reaction mixture was stirred. After 10 min, isobutyl chloroformate (1.1 eq) was added dropwise by syringe, during which time a white precipitate formed. The reaction mixture was stirred vigorously for 5 h. The anhydride generated was used directly in the next step. 
Synthesis of 14 C-labeled acetylated mannosamine derivatives
[1-14 C]-Mannosamine hydrochloride (0.9 µmol, 50 µCi) was dissolved in 20 µl of 50 mM NaOMe in MeOH in an eppendorf tube and allowed to react for 2 h. A solution of the desired alkyl anhydride in MeOH (1.1 µmol, 2 µl of a 550 mM solution) was added, and the reaction was allowed to proceed overnight. The reaction was followed by tlc (5:1 CHCl 3 :MeOH) and the tlc plate was visualized by phosphorimaging. When the reaction was complete, the solvent was evaporated and the residue was purified by silica gel chromatography, eluting with a gradient of 9 20:1 to 5:1 CHCl 3 :MeOH. Fractions containing radioactivity at the correct R F were combined and the solvent was removed. The resulting pure mannosamine derivative was dissolved in 50 µl of pyridine, to which was added 25 µl of acetic anhydride. Progress of the reaction was followed by tlc (EtOAc). Upon completion, the solvents were removed, the residue was dissolved in EtOH, and the yield was determined by scintillation counting of 0.1% of the solution.
14 C-labeled compounds were characterized by ESI mass spectroscopy, confirming the absence of contaminating 14 C-labeled peracetylated ManNAc ( 14 C-Ac 4 ManNAc, compound 9c) in the unnatural derivatives.
Quantification of cell surface ketones
Cell-surface ketones were quantified after incubating cells with unprotected or peracetylated sugars for two days. Generally, concentrations of 5 mM unprotected sugar or 10-50 µM acetylated sugar were used. The cells were labeled with biotin hydrazide followed by FITCavidin staining according to a previously published procedure (18, 20) .
Colorimetric analysis of sialic acids using N-acyl substrates.
The appropriate volume of a solution of the desired compound (100 mM in ethanol, compounds 9b -13b) was added to 8.0 ml of Jurkat cells at a density of 1x10 6 
Analysis of cytosolic metabolites produced from radiolabeled substrates.
Jurkat cells were incubated at a density of 1x10 6 cells/100 µl in a 96-well tissue culture plate with 200 nCi of peracetylated 14 C-mannosamine derivatives. Unlabeled substrate was added 11 in some cases, in varying concentrations up to 200 µM. The addition of cytidine (1 mM) was used in some cases to increase conversion of sialic acid to CMP-sialic acid. Cells were incubated for 20 h, then pelleted and washed twice with 0.5 ml of PBS. Cells were then suspended in 150 µl water and lysed by four freeze/thaw cycles, after which time the samples were maintained at 4°C
. The lysate was cleared of macromolecules using Microcon filters (Millipore), 30,000 and 3,000 kDa cut-off, sequentially. The cleared lysate was dried and dissolved in 80 µl of water, and 20 µl aliquots were analyzed by HPAEC followed by flow scintillation counting. Two different gradients were used to ensure that peaks corresponded to authentic standards. Gradient A: 25 mM NaOH for 10 min; ramp to 45 mM NaOH, 200 mM NaOAc over 15 min; ramp to 140 mM NaOH, 300 mM NaOAc over 15 min and hold for 15 min; ramp to 25 mM NaOH over 5 min and hold for 20 min. Gradient B: ramp from 25 mM NaOH to 50 mM NaOH, 200 mM NaOAc over 10 min; ramp to 140 mM NaOH, 600 mM NaOAc over 5 min and hold 5 min; ramp to 25 mM NaOH over 5 min and hold for 10 min. Peaks were identified by comparing elution times to those of authentic standards. ManNAc, sialic acid and CMP-sialic acid standards were commercially available. ManNAc-6-phosphate was chemo-enyzmatically synthesized using hexokinase (24) .
Peaks were integrated using Flo-ONE analysis software (Packard, Meriden, CT).
In vitro enzyme assay for ManNAc 6-kinase
Human UDP-GlcNAc 2-epimerase/ManNAc 6-kinase was overexpressed in Sf9 cells as previously reported (25) . The cells (about 100 µl pellet volume) were lysed in 1 ml of 10 mM NaH 2 PO 4 with 1 mM EDTA, 1 mM DTT (pH 7.5) and 1 µl of protease inhibitor cocktail (1 mg/ml leupeptin, 2 mg/ml antipain, 20 mg/ml turkey trypsin inhibitor, 10 mg/ml benzamidine, 5 mg/ml Pefabloc®, 2 mg/ml aprotinin) by 20 passages through a narrowbore needle. The cytosol was clarified by centrifugation (16,000 x g for 30 min at 4 ºC). The supernatant was purified on a HiTrap Q Sepharose column (Pharmacia, Sweden) as follows: the column was loaded with the clarified cytosol and washed with 5 ml of 10 mM NaH 2 PO 4 , 1 mM EDTA, 1 mM DTT (pH 7.5) 12 and the protein was eluted in the same buffer using a gradient of 0 to 600 mM NaCl over 10 ml (0.5-ml fractions). The desired protein (MW = 75 kD) eluted in approximately 300 mM NaCl and was approximately 90% pure as determined by SDS-PAGE analysis (10% gel, Coomasie stain).
Purified enzyme (10 µl) was added to a preincubated mixture that contained 5 mM desired substrate, 10 mM ATP, 2 mM PEP, 0.2 mM NADH, 2 U of pyruvate kinase and 2 U of lactate dehydrogenase in 60 mM Tris, 10 mM MgCl 2 , pH 8.1 (total reaction volume = 0.1 ml).
The enzymatic reaction was monitored at 340 nm with a SpectraMAX 190 UV/vis microplate reader (Molecular Devices) over 15 min or until the reaction rate began to plateau. Initial rates were determined using SOFTmax® PRO 3.1 software (Molecular Devices).
Results
Synthesis of mannosamine derivatives
We designed a panel of mannosamine analogs, shown in Figure 2A , bearing side chains that are longer, shorter or more sterically demanding than the five-carbon side chain of ManLev (compound 3). Compound 2 has an acetoacetyl side chain that is one methylene unit shorter than the side chain of ManLev, and compounds 4-6 have successively longer side chains of six, seven or eight carbon atoms, respectively. Compounds 7 and 8 have side chains of the same length as found in ManLev, but present greater steric demands due to an added methyl group (7) or cyclopentanone ring (8) . Finally, compound 1 is isosteric with the native substrate ManNAc;
substitution of the NH group with a methylene group generates the ketone functionality (26) .
Some compounds were prepared in both free (a) and peracetylated (b) forms to address possible differences in cellular uptake of the unprotected mannosamine analogs (vide infra).
Cellular metabolism of unnatural ketone-containing mannosamine analogs
Jurkat cells were incubated with compounds 2 and 3a -8a (5 mM, 2 days) and evaluated for metabolic incorporation of the corresponding sialic acids into cell-surface glycoconjugates by 13 staining with biotin hydrazide followed by FITC-avidin (18) . To investigate whether these analogs function as inhibitors rather than substrates of the pathway, we co-incubated ManLev with the eight-carbon analog 6a. No reduction in ketone expression was observed at concentrations of 6a that were three-fold higher than ManLev, suggesting that 6a is not blocking normal metabolic processes (Supporting Information).
The human cell lines HL-60 and HeLa were also incubated with the unnatural mannosamines. The results from these experiments echoed observations from the similar experiment using Jurkat cells (Supporting Information). These results suggest that metabolic discrimination between ManLev and larger, untolerated analogs is a general feature of the human sialic acid biosynthetic machinery. These cell lines exhibit different patterns of glycosylation, including varying levels of α2-3 and α2-6 linked sialic acids as determined by lectin binding studies (Supporting Information). In addition, we have previously demonstrated the incorporation of N-levulinoyl sialic acid into CD43 bearing α2-3-linked sialic acids (27) and NCAM bearing α2-8-linked sialic acids (28), suggesting the corresponding sialyltransferases are similarly 14 tolerant of the unnatural side chain. Overall, these results suggest that sialyltransferases are relatively uniform in their permissivity toward unnatural CMP-sialic acids.
Peracetylated monosaccharides have been shown to passively diffuse through mammalian cell membranes and undergo subsequent deacetylation by cytosolic or ER esterases (29) . We hypothesized that any discrimination against unnatural substrates at the level of cellular uptake would be circumvented by their acetylation. We therefore synthesized peracetylated monosaccharides 1 and 3b -8b and incubated them with Jurkat cells for two days at concentrations of 50-100 µM. Interestingly, compound 1, the analog most similar to ManNAc in structure but lacking the hydrogen-bonding capability of the amide NH, was not converted to cell-surface sialosides at a detectable level. Compounds 3b -8b were converted into cell-surface sialosides at the same relative level as their unprotected counterparts ( Figure 3 ). Specifically, compound 3b was metabolized to a significant extent, while the longer or bulkier N-acyl analogs were metabolized to a lesser or undetectable extent. Since the mechanism of cellular uptake does not affect the metabolic fate of these derivatives, we conclude that their discrimination occurs at a downstream step in the process.
A substantial practical benefit of the peracetylated sugars is that these protected mannosamines can be utilized at concentrations approximately 200-fold less than the free sugars while producing similar levels of cell-surface ketones (30) . Since this effect was seen for all mannosamines tested thus far, in most subsequent experiments the more efficient peracetylated mannosamines were used for cellular assays.
Colorimetric analysis of cellular sialic acids produced from N-acyl mannosamine analogs
In order to determine whether unnatural mannosamines were being converted to sialic acids inside the cells, we analyzed the intracellular concentrations of total (reducing and nonreducing) and glycoside-bound (non-reducing only) sialic acids using cells treated with different substrates. The two forms of sialic acid can be discriminated by the periodate-resorcinol assay; 15 oxidation at 0 ºC measures total sialic acid, and oxidation at 37 ºC measures glycoside-bound sialic acid. The concentration of free (reducing) sialic acid can be determined by subtracting the latter from the former. The results of periodate-resorcinol assays are shown in Figure 4 .
We observed a substrate concentration-dependent increase in total cellular sialic acid levels that was inversely correlated with the length of the substrate's N-acyl side chain ( Figure   4A ). Not surprisingly, the natural substrate Ac 4 ManNAc (compound 9b) produced the largest increase in total sialic acid levels, although Ac 4 ManProp (10b) also supported significant levels of sialic acid production. 
Mass spectral analysis and quantification of cytosolic sialic acids
To definitively prove the identity of the sialic acids derived from unnatural substrates, we performed mass spectrometry analysis of the cytosolic components of the cell. Jurkat cells were incubated with the acetylated mannosamine derivatives, harvested and their cytosolic components were prepared for mass spectral analysis. In a control experiment, Jurkat cells were treated with ( Figure 5C ), 336.3 ( Figure 5D ), and 350.3 ( Figure 5E ), respectively. When Jurkat cells were incubated with Ac 4 ManLev (3b) at 200 µM, no mass signal at 364.3 could be detected ( Figure   5F ). In order to compare unnatural sialic acid levels across the substrate panel, an internal standard ( 13 C-NeuAc, m/z at 309.3) was added to the sample during analysis. Such comparisons revealed that the amount of sialic acid analog within the cell decreased as the alkyl chain length on the N-acyl position of mannosamine increased. The absence of a detectable peak for unnatural sialic acid in ManLev-treated cells suggests that the ketone group further diminishes conversion to sialic acid compared to the methylene analog ManPent.
Analysis of cytosolic mannosamine metabolites using 14 C-Ac 4 ManNAc
In order to dissect all intermediates in the biosynthetic pathway, we developed an HPAEC assay that quantified the products from radiolabeled mannosamine analogs. Initially, Jurkat cells were treated with 14 C-Ac 4 ManNAc (9c) along with various concentrations of unlabeled Ac 4 ManNAc, with or without added cytidine. Figure 6A shows HPAEC traces that clearly define each intermediate along the pathway, with the exception of sialic acid-9-phosphate, which is presumably present in quantities too minute to be detected. Furthermore, the peak area ratios varied with added unlabeled substrate and added cytidine in a predictable fashion, thereby assuring that the assay is sensitive enough to sense changes in the flux of the pathway. In order to determine the length of incubation that would result in optimal conversion of radiolabeled substrates, a time course was performed using compound 9c ( Figure 6B ). This experiment indicated that, at least for Ac 4 ManNAc, conversion of exogenous peracetylated substrate to cytosolic intermediates was optimal between 20 and 24 hours.
Analysis of cytosolic unnatural mannosamine metabolites using 14 C-labeled N-acyl substrates
A panel of unnatural 14 C-labeled N-acyl mannosamines was used in metabolic radiolabeling experiments as described above to determine the efficiency of transformation of each unnatural mannosamine to its downstream products, as compared to the natural substrate. Figure 7A shows the HPAEC/flow scintillation traces generated using this substrate panel. The retention times of peaks changed slightly depending on the substrate used, due to the increased 
In vitro assay of ManNAc 6-kinase activity using unnatural substrates
Since it appeared from cell-based assays that unnatural mannosamine derivatives were not being efficiently phosphorylated in the first step of the biosynthetic pathway, we performed in vitro assays with the enzyme responsible for this activity, ManNAc 6-kinase (31) . The enzyme exists as part of a bifunctional protein that catalyzes the formation of ManNAc from UDPGlcNAc and its subsequent phosphorylation. The kinase also acts on exogenously added
ManNAc (25) . Using the partially purified human enzyme that had been overexpressed in Sf9 insect cells, we tested the panel of mannosamine derivatives as substrates in a coupled enzyme spectrophotometric assay (25) . The screen was performed using ATP at a concentration of 10 mM and the desired substrate at 5 mM. As shown in Figure 9 , the enzyme showed reduced activity toward unnatural substrates. ManProp and ManLev were phosphorylated at an initial rate about 6-fold lower than the natural substrate, and ManBut and ManPent were not measurably turned over by the enzyme. The activity of the partially purified enzyme toward GlcNAc was also tested to confirm the absence of other contaminating sugar kinases, i.e. GlcNAc kinase. Clearly, this initial step of the sialic acid pathway is quite restrictive with respect to unnatural substrates.
Discussion
In this study we probed the unnatural substrate tolerance of the sialoside biosynthetic pathway toward C-2 modifications of ManNAc. In an initial cell-based assay, which exploits a uniquely reactive ketone group within cell-surface metabolic products, substrate tolerance of the 19 entire pathway could be probed without perturbing the subcellular organization of its components. In contrast to conventional biochemical assays for substrate recognition, this approach tests all biosynthetic enzymes at once, along with intracellular transporters, and lends itself to high-throughput analysis by flow cytometry.
We found that substitution of the amide group at C-2 of ManNAc with a ketone, as in compound 1, disrupted processing of this compound by the sialoside biosynthetic pathway. This could be attributed to subtle changes in structure or the loss of key hydrogen bonding interactions, preventing binding to an active site or catalytic activity. The amide group at C-2 is therefore a critical determinant that cannot be replaced in an unnatural sialic acid precursor.
A major finding of these initial experiments is that the sialic acid biosynthetic pathway is highly sensitive to elongation of the side chain beyond five carbon atoms. Extension of the chain to six, seven or eight carbon atoms caused a precipitous drop in the efficiency (compared to smaller N-acyl groups) of metabolism to cell surface sialosides in all cell lines tested. Moreover, subtle increases in steric bulk, such as methylation or addition of a ring, also compromised metabolic conversion to the cell surface product in all cell lines tested. Thus, one or more enzymes or transporters in the pathway are unable to transform the larger analogs. The initial step, uptake of the analogs from the media, was ruled out as a point of stringency or "bottleneck" since peracetylated derivatives were metabolized to sialosides at the same relative levels as the free sugars. Since exclusion of the longer N-acyl chains was largely independent of the type of sialic acid linkages found on the cells, one or more steps prior to the sialyltransferases is most likely responsible for the initial metabolic blockade.
To explore the intracellular basis for the differential cell surface expression of various unnatural sialosides, we developed colorimetric, mass spectral and radiolabel HPLC assays using whole-cell lysates to quantify metabolic intermediates. These assays were applied to determine which biosynthetic step or steps are responsible for the discrimination between substrates observed by flow cytometry. Using a colorimetric assay to detect total cellular or non-reducing 20 sialic acid, we confirmed that the amount of detectable sialic acid decreases with increasing chain length of the mannosamine substrate. Mass spectral analysis corroborated these results.
Interestingly, two substrates of identical side chain length can have different metabolic conversion efficiencies. Ac 4 ManLev (3b), bearing a five-carbon ketone-containing side chain, produced sialic acid levels that were below the mass spectrometry detection limit, while the similar compound Ac 4 ManPent (12b), lacking a ketone, generated a small but detectable amount of the corresponding sialic acid.
We used a radiolabel HPAEC assay to measure the relative levels of multiple intermediates of the pathway at once. The observation of a build-up of any individual intermediate derived from an unnatural mannosamine indirectly implicates the previous enzymatic step as a bottleneck for unnatural sialoside biosynthesis. Results generated using the 14 C-labeled panel, compounds 9c -13c, as well as in vitro enzyme assays indicated that ManNAc 6-kinase is intolerant of even modest changes in substrate structure such that unnatural products cannot accumulate to detectable levels. However, cells fed unnatural compounds 10, 11 and 12 generated detectable amounts of sialic acid. It is possible that N-acylmannosamines are converted directly into sialic acids by sialic acid-9-phosphate synthase, bypassing the phosphorylation step entirely. However, previous in vitro assays did not detect any synthase activity on unphosphorylated ManNAc (32). Sialic acid aldolase, which normally operates in the direction of sialic acid decomposition, might also be capable of converting unnatural mannosamines into sialic acids under the right cellular conditions. Indeed, a bacterial homologue has been shown to be quite permissive with respect to the N-acyl position of the substrate (33) . Additionally, GlcNAc 6-kinase can utilize ManNAc as a substrate, albeit with 100-fold lower efficiency than GlcNAc, providing an alternative route to ManNAc-6-phosphate from ManNAc (34) .
Using unnatural substrates, we did not observe the accumulation of ManX-6-phosphate in cells. Thus, any ManX-6-phosphate that is generated by the action of either ManNAc or GlcNAc 6-kinase must be immediately converted to sialic acid, suggesting that the two intervening 21 enzymes (sialic acid 9-phosphate synthase and sialic acid 9-phosphate phosphatase) are relatively more permissive.
In conclusion, we have identified ManNAc 6-kinase as a bottleneck step in the biosynthesis of unnatural sialic acids. This enzyme is therefore an attractive target for genetic engineering with the goals of relaxing substrate specificity and expanding the scope of sialic acidbased cell surface engineering. We think it likely that enzymes further downstream are also contributing to unnatural substrate discrimination; it is possible that multiple bottlenecks exist.
Further biochemical and metabolic experiments should identify additional enzyme targets for genetic engineering.
